# Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant

> **NCT03359746** · PHASE4 · UNKNOWN · sponsor: **King Faisal Specialist Hospital & Research Center** · enrollment: 40 (estimated)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Grazoprevir/Elbasvir

## Key facts

- **NCT ID:** NCT03359746
- **Lead sponsor:** King Faisal Specialist Hospital & Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-15
- **Primary completion:** 2018-10-31
- **Final completion:** 2018-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2017-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03359746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03359746, "Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03359746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*